Abstract:MHC class II (MHCII) genes are transactivated by the NOD-like receptor (NLR) family member CIITA, which is recruited to SXY enhancers of MHCII promoters via a DNA-binding "enhanceosome" complex. NLRC5, another NLR protein, was recently found to control transcription of MHC class I (MHCI) genes. However, detailed understanding of NLRC5's target gene specificity and mechanism of action remained lacking. We performed ChIP-sequencing experiments to gain comprehensive information on NLRC5-regulated genes. In addition to classical MHCI genes, we exclusively identified novel targets encoding non-classical MHCI molecules having important functions in immunity and tolerance. ChIP-sequencing performed with Rfx5(-/-) cells, which lack the pivotal enhanceosome factor RFX5, demonstrated its strict requirement for NLRC5 recruitment. Accordingly, Rfx5-knockout mice phenocopy Nlrc5 deficiency with respect to defective MHCI expression. Analysis of B cell lines lacking RFX5, RFXAP, or RFXANK further corroborated the importance of the enhanceosome for MHCI expression. Although recruited by common DNA-binding factors, CIITA and NLRC5 exhibit non-redundant functions, shown here using double-deficient Nlrc5(-/-)CIIta(-/-) mice. These paradoxical findings were resolved by using a "de novo" motif-discovery approach showing that the SXY consensus sequence occupied by NLRC5 in vivo diverges significantly from that occupied by CIITA. These sequence differences were sufficient to determine preferential occupation and transactivation by NLRC5 or CIITA, respectively, and the S box was found to be the essential feature conferring NLRC5 specificity. These results broaden our knowledge on the transcriptional activities of NLRC5 and CIITA, revealing their dependence on shared enhanceosome factors but their recruitment to distinct enhancer motifs in vivo. Furthermore, we demonstrated selectivity of NLRC5 for genes encoding MHCI or related proteins, rendering it an attractive target for therapeutic intervention. NLRC5 and CIITA thus emerge as paradigms for a novel class of transcriptional regulators dedicated for transactivating extremely few, phylogenetically related genes.

NLRC5 Deficiency Selectively Impairs MHC Class I- Dependent Lymphocyte Killing by Cytotoxic T Cells

NLRC5 regulates MHC class I antigen presentation in host defense against intracellular pathogens

Enhanced TLR-induced NF-κB Signaling and Type I Interferon Responses in NLRC5 Deficient Mice

Role of NLRC5 and IRF1 in the induction of MHC class I

Cutting Edge: Impaired MHC Class I Expression in Mice Deficient for Nlrc5/Class I Transactivator

Expression regulation and function of NLRC5

NLRC5 Exclusively Transactivates MHC Class I and Related Genes through a Distinctive SXY Module

The N-Terminal Domain of NLRC5 Confers Transcriptional Activity for MHC Class I and II Gene Expression

NLRC5 negatively regulates the NF-kappaB and type I interferon signaling pathways

NLRC5 Negatively Regulates the NF-κB and Type I Interferon Signaling Pathways

NLRC5: a key regulator of MHC class I-dependent immune responses

NLRC5/MHC class I transactivator is a target for immune evasion in cancer

NLRC5 Cooperates with the RFX Transcription Factor Complex To Induce MHC Class I Gene Expression

NLRC5: back to innate immunity

NLRC5 deficiency has a moderate impact on immunodominant CD8+ T-cell responses during rotavirus infection of adult mice

The balance between nuclear import and export of NLRC5 regulates MHC class I transactivation

CITA/NLRC5: A critical transcriptional regulator of MHC class I gene expression

NLRC5: A Paradigm for NLRs in Immunological and Inflammatory Reaction.

Reversible Ubiquitination Shapes NLRC5 Function and Modulates NF-κB Activation Switch

NLRC5 regulates expression of MHC-I and provides a target for anti-tumor immunity in transmissible cancers

Emerging Roles for NLRC5 in Immune Diseases